Vis enkel innførsel

dc.contributor.authorCunningham, Evan B
dc.contributor.authorHajarizadeh, Behzad
dc.contributor.authorDalgard, Olav
dc.contributor.authorAmin, Janaki
dc.contributor.authorHellard, Margaret
dc.contributor.authorFoster, Graham R
dc.contributor.authorBruggmann, Philip
dc.contributor.authorConway, Brian
dc.contributor.authorBackmund, Markus
dc.contributor.authorRobaeys, Geert
dc.contributor.authorSwan, Tracy
dc.contributor.authorMarks, Philippa S
dc.contributor.authorQuiene, Sophie
dc.contributor.authorApplegate, Tanya L
dc.contributor.authorWeltman, Martin
dc.contributor.authorShaw, David
dc.contributor.authorDunlop, Adrian
dc.contributor.authorBruneau, Julie
dc.contributor.authorMidgard, Håvard
dc.contributor.authorBourgeois, Stefan
dc.contributor.authorThurnheer, Maria Christine
dc.contributor.authorDore, Gregory J
dc.contributor.authorGrebely, Jason
dc.contributor.authorShaw, Ineke
dc.contributor.authorSiriragavan, Sharmila
dc.contributor.authorHorschik, Tina
dc.contributor.authorSharma, Shawn
dc.contributor.authorEevers, Anita
dc.contributor.authorAndreassen, Jessica
dc.contributor.authorMelkeraaen, Ingunn
dc.contributor.authorWidder, Nicole
dc.contributor.authorLesneuck, Kristof
dc.contributor.authorKotsoros, Barbara
dc.contributor.authorHazelwood, Susan
dc.contributor.authorHolland, Rohan
dc.contributor.authorAxten, David
dc.contributor.authorVon Bibra, Sally
dc.contributor.authorPowis, Jeff
dc.contributor.authorMason, Kate
dc.contributor.authorRyder, Stephen
dc.contributor.authorJack, Kate
dc.contributor.authorScheidegger, Claude
dc.contributor.authorHuber, Christine
dc.contributor.authorFerguson, Catherine
dc.contributor.authorStaehelin, Cornelia
dc.contributor.authorLacalamita, Melanie
dc.contributor.authorFragomeli, Vincenzo
dc.contributor.authorSevehon, Alison
dc.date.accessioned2019-07-12T07:12:21Z
dc.date.available2019-07-12T07:12:21Z
dc.date.issued2017-06-13
dc.identifier.citationCunningham, E. B., Hajarizadeh, B., Dalgard, O., Amin, J., Hellard, M., Foster, G. R., ... & Swan, T. (2017). Adherence to response-guided pegylated interferon and ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: the ACTIVATE study. BMC infectious diseases, 17(1), 420.en
dc.identifier.issn1471-2334
dc.identifier.urihttps://hdl.handle.net/10642/7273
dc.description.abstractBackground The aims of this analysis were to investigate treatment completion and adherence among people with ongoing injecting drug use or receiving opioid substitution therapy (OST) in a study of response-guided therapy for chronic HCV genotypes 2/3 infection. Methods ACTIVATE was a multicenter clinical trial recruited between 2012 and 2014. Participants with genotypes 2/3 were treated with directly observed peg-interferon alfa-2b (PEG-IFN) and self-administered ribavirin for 12 (undetectable HCV RNA at week 4) or 24 weeks (detectable HCV RNA at week 4). Outcomes included treatment completion, PEG-IFN adherence, ribavirin adherence, and sustained virological response (SVR, undetectable HCV RNA >12 weeks post-treatment). Results Among 93 people treated, 59% had recently injected drugs (past month), 77% were receiving OST and 56% injected drugs during therapy. Overall, 76% completed treatment. Mean on-treatment adherence to PEG-IFN and ribavirin were 98.2% and 94.6%. Overall, 6% of participants missed >1 dose of PEG-IFN and 31% took <95% of their prescribed ribavirin., Higher treatment completion was observed among those receiving 12 vs. 24 weeks of treatment (97% vs. 46%, P < 0.001) while the proportion of participants with 95% on-treatment ribavirin adherence was similar between groups (67% vs. 72%, P = 0.664). Receiving 12 weeks of therapy was independently associated with treatment completion. No factors were associated with 95% RBV adherence. Neither recent injecting drug use at baseline nor during therapy was associated with treatment completion or adherence to ribavirin. In adjusted analysis, treatment completion was associated with SVR (aOR 23.9, 95% CI 2.9–193.8). Conclusions This study demonstrated a high adherence to directly observed PEG-IFN and self-administered ribavirin among people with ongoing injecting drug use or receiving OST. These data also suggest that shortening therapy from 24 to 12 weeks can lead to improved treatment completion. Treatment completion was associated with improved response to therapy.en
dc.language.isoenen
dc.publisherBMC Springeren
dc.relation.ispartofseriesBMC Infectious Diseases;17(1)
dc.rightsAttribution-NonCommercial-NoDerivs 3.0 United States This is an open access article originally published at https://doi.org/10.1186/s12879-017-2517-3en
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/3.0/us/*
dc.subjectVDP::Medisinske Fag: 700en
dc.subjectArtikkelen
dc.titleAdherence to response-guided pegylated interferon and ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: The ACTIVATE studyen
dc.typeJournal articleen
dc.typePeer revieweden
dc.description.versionpublishedVersionen
dc.identifier.doihttps://doi.org/10.1186/s12879-017-2517-3
dc.identifier.cristin1550777


Tilhørende fil(er)

Thumbnail

Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel

Attribution-NonCommercial-NoDerivs 3.0 United States
This is an open access article originally published at https://doi.org/10.1186/s12879-017-2517-3
Med mindre annet er angitt, så er denne innførselen lisensiert som Attribution-NonCommercial-NoDerivs 3.0 United States This is an open access article originally published at https://doi.org/10.1186/s12879-017-2517-3